☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Biocytogen
Biocytogen and Gilead Partner to Select and Develop Therapeutic Targets for the Treatment of Multiple Diseases
February 21, 2024
Biocytogen and Neurocrine Biosciences Sign an Antibody Evaluation and Option Agreement
December 20, 2023
Biocytogen Entered into a License Agreement with Pheon Therapeutics to Develop Antibody-Drug Conjugate for Cancer
July 6, 2023
Biocytogen’s Subsidiary Eucure Biopharma Signs an Exclusive License Agreement with Chipscreen’s Holding Subsidiary Chipscreen NewW...
February 28, 2023
Biocytogen Enters into Evaluation and Option Agreement with ADC Therapeutics for Antibody-Based Therapies
November 29, 2022
Biocytogen Entered into an Agreement with CtM Biotech to Co-develop TCR-Mimic Antibody-Based Multi-Specific T Cell Engagers for Ca...
April 19, 2022
Load more...
Back to Home
Modal title
×
Modal body text goes here.